TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Schuhmacher, Alexander
A1  - Gatto, Alexander
A1  - Hinder, Markus
A1  - Kuss, Michael
A1  - Gassmann, Oliver
T1  - The upside of being a digital pharma player
JF  - Drug discovery today
N2  - We investigated the state of artificial intelligence (AI) in pharmaceutical research and development (R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the research area, a combined qualitative and quantitative research method was chosen, including the analysis of annual company reports, investor relations information, patent applications, and scientific publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that the industry is in an ‘early mature’ phase of using AI in R&D. Furthermore, we can demonstrate that, despite the efforts that need to be managed, recent developments in the industry indicate that it is worthwhile to invest to become a ‘digital pharma player’.
Y1  - 2020
SN  - 1359-6446
SS  - 1359-6446
U6  - https://doi.org/10.1016/j.drudis.2020.06.002
DO  - https://doi.org/10.1016/j.drudis.2020.06.002
VL  - 25
IS  - 9
SP  - 1569
EP  - 1574
S1  - 6
PB  - Elsevier
CY  - Amsterdam
ER  -